Idorsia Ltd IDRSF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.40
- Day Range
- $5.38–5.38
- 52-Week Range
- $3.50–8.19
- Bid/Ask
- $13.14 / $13.58
- Shares Outstanding
- 269.06M
- Market Cap
- $1.37B
- Volume/Avg
- 10,952 / 10,290
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.22
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 232
- Website
- https://www.idorsia.com
Valuation
|
Metric
|
IDRSF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 5.22 |
Price/Cash Flow | — |
Price/Earnings
IDRSF
Financial Strength
|
Metric
|
IDRSF
|
|---|---|
Quick Ratio | 0.36 |
Current Ratio | 0.58 |
Interest Coverage | −3.64 |
Quick Ratio
IDRSF
Profitability
|
Metric
|
IDRSF
|
|---|---|
Return on Assets (Normalized) | −24.98% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −40.80% |
Return on Assets
IDRSF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|n#!dsK! | LOCK|gP^Qg | $129B | |||
| Moderna Inc
MRNA
| LOCK|%@>^S!& | LOCK|X#! | $94B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@n>dq< | LOCK|N#W& | $82B | |||
| argenx SE ADR
ARGX
| LOCK|XnCpbf | LOCK|JF | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Nq&mns | LOCK|@@? | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|lNM<j< | LOCK|#bMc | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@!#m<D@& | LOCK|&X@^ | $27B | |||
| Incyte Corp
INCY
| LOCK|W>ZF?! | LOCK|SMN | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$!<&!q< | LOCK|Yp | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|l&$KVkY | LOCK|gh | $14B |
United States